Convatech BV, a Dutch-based pharmaceutical contract research organization company, is pleased to announce that Gert Jan Ettema will become the new Managing Director of Convatech. Gert Jan succeeds Hans Platteeuw, founder of Convatech, who will take a seat as a member of the Supervisory Board.

Gert Jan will lead the company into the next phase by expanding and strengthening the contract R&D activities with a results-driven focus on creating value for Convatech’s partners.

Hans Platteeuw: “After 17 years of hard work and providing all my knowledge and expertise at Convatech to customers, time has come to step aside and hand over the business. Gert Jan has gained a wealth of knowledge in developing new drug products, generics, and value-added medicines over the past 28 years when employed as an organic chemist, project manager & portfolio manager at Synthon, MSD, and Chemconnection. The combination of his broad technical and management experience and his passion for the development of new and value-added medicines make him the ideal next Managing Director for Convatech.

Gert Jan Ettema: “There is a clear market need for experienced, pragmatic, result-driven, and scientifically sound development capacity to create safe and effective dosage forms for new and repurposed drugs. I am proud to be part of Convatech’s experienced team in supporting companies in the challenging but very exciting environment of drug product development.”